Bladder, prostate and other urinary tract diseases cost Americans nearly $11 billion a year, according to a new report from the National Institutes of Health. Medicare?s share exceeded $5.4 billion.
GlaxoSmithKline (GSK) and The Wellcome Trust today announced a collaboration to develop a new class of antibacterial to combat the rise of certain drug-resistant hospital-acquired infections, including those that lead to pneumonia.
In 1928, Alexander Fleming opened the door to treating bacterial infections when he stumbled upon the first known antibiotic in a penicillium mold growing in a discarded experiment.
The National Institutes of Health has awarded $7 million to a team of researchers from the University of Illinois and the University of Wisconsin to discover, engineer and produce a promising — yet little explored — class of antibiotic agents.
Wan, et al evaluated 95 infants who presented with a urinary tract infection. They reviewed the clinical and laboratory findings as well as the diagnosis and treatment.
A surprising new theory developed at the University of Nebraska Medical Center (UNMC) in Omaha, Nebraska, suggests that some bacterial cells act as ?suicide bombers? in cell communities, with the altruistic intention of dying for the common good ? and in the process, strengthening other cells that then become resistant to antibiotic drugs.
Researchers from the Schulich School of Medicine & Dentistry at The University of Western Ontario , working with a group from Edinburgh, have discovered a way to kill the cystic fibrosis superbug, Burkholderia cenocepacia.
Researchers at the University of Pennsylvania School of Medicine have discovered that an enzyme produced by lung-infecting bacteria further shuts down a protein that is defective in cystic fibrosis patients.
Researchers from the University of Washington, Rosalind Franklin University of Medicine and Science, Merck Laboratories, and Mount Sinai School of Medicine have released a study suggesting that specific laboratory and clinical tests can predict outcome of antibiotic therapy for infections in persons with diabetes.
The Food and Drug Administration (FDA) approved Altabax (retapamulin ointment) for topical treatment of impetigo, a skin infection caused by bacteria. Altabax is indicated for use in patients aged nine months or older.